将抗癌药物转化成无活性的前体药物，然后用肿瘤特异的单克隆抗体（mAb）导向的酶一抗体偶联物在肿瘤部位活化前体药物，使之在肿瘤局部转化成有活性的药物是一种肿瘤导向化疗的新方法。以mAb的特异性及酶的高效催化活性为一体的方法，可使每一种酶一抗体偶联物在肿瘤局部形成 The anticancer drug is converted to an inactive prodrug which is then activated with a tumor-specific monoclonal antibody (mAb) directed enzyme-antibody conjugate to activate the prodrug at the tumor site and locally convert the tumor drug into an active Drugs are a new approach to tumor-directed chemotherapy. Taking the specificity of mAb and the efficient catalytic activity of the enzyme as a whole, each enzyme-antibody conjugate can be formed locally in the tumor